Drugs / Slurimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06014944 | Sep 2023 → Dec 2028 expected | rectal cancer | Changhai Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Slurimab | “furoquintinib combined with slurimab, furoquintinib 5 mg / time / day” NCT06014944 ↗ |